Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
© 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular...
Saved in:
Main Authors: | Young Rok Do, Jae Yong Kwak, Jeong A. Kim, Hyeoung Joon Kim, Joo Seop Chung, Ho Jin Shin, Sung Hyun Kim, Udomsak Bunworasate, Chul Won Choi, Dae Young Zang, Suk Joong Oh, Saengsuree Jootar, Ary Harryanto Reksodiputro, Won Sik Lee, Yeung Chul Mun, Jee Hyun Kong, Priscilla B. Caguioa, Hawk Kim, Jinny Park, Dong Wook Kim |
---|---|
Other Authors: | Wonju Severance Christian Hospital |
Format: | Article |
Published: |
2020
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/53884 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia
by: Jae Yong Kwak, et al.
Published: (2018) -
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
by: Sung Hyun Kim, et al.
Published: (2018) -
Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib
by: Sung Eun Lee, et al.
Published: (2019) -
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)
by: Hagop Kantarjian, et al.
Published: (2018) -
Impact of molecular response time achievement on survival of chronic phase chronic myelogenous leukemia patients treated by imatinib
by: Putu Niken Ayu Amrita, et al.
Published: (2020)